Evidence map›Paper›PMID 36640333›Full record

ArticleCell reports2023

Cell-specific cargo delivery using synthetic bacterial spores.

Minsuk Kong, Domenico D'Atri, Maria Teresa Bilotta, Bailey Johnson, Taylor B Updegrove, Devorah L Gallardo, Federico Machinandiarena, I-Lin Wu, Maira Alves Constantino, Stephen M Hewitt and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Minsuk KongLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Food Science and Technology, Seoul National University of Science and Technology, Seoul 01811, South Korea.
Domenico D'AtriLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Maria Teresa BilottaLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Bailey JohnsonLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Taylor B UpdegroveLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Devorah L GallardoLaboratory Animal Sciences Program, Leidos Biomedical Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Federico MachinandiarenaLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
I-Lin WuLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Maira Alves ConstantinoLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Stephen M HewittLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Kandice TannerLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: kandice.tanner@nih.gov.
David J FitzgeraldLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: fitzgerd@mail.nih.gov.
Kumaran S RamamurthiLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: ramamurthiks@mail.nih.gov.
National Institutes of Health · USLeidos (United States) · USSeoul National University of Science and Technology · KR

Funding

Subcellular protein localization in B. subtilisZIABC011211 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RAMAMURTHI, KUMARAN · 2009 to 2025
$21.4M
Bio-Therapies for the Treatment of Cancer and Infectious DiseaseZIABC008757 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FITZGERALD, DAVID · 2009 to 2025
$21.0M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Delivery of cancer therapeutics to non-specific sites decreases treatment efficacy while increasing toxicity. In ovarian cancer, overexpression of the cell surface marker HER2, which several therapeutics target, relates to poor prognosis. We recently reported the assembly of biocompatible bacterial spore-like particles, termed "SSHELs." Here, we modify SSHELs with an affibody directed against HER2 and load them with the chemotherapeutic agent doxorubicin. Drug-loaded SSHELs reduce tumor growth and increase survival with lower toxicity in a mouse tumor xenograft model compared with free drug and with liposomal doxorubicin by preferentially accumulating in the tumor mass. Target cells actively internalize and then traffic bound SSHELs to acidic compartments, whereupon the cargo is released to the cytosol in a pH-dependent manner. We propose that SSHELs represent a versatile strategy for targeted drug delivery, especially in cancer settings.

Indexed as

NeoplasmsSpores, BacterialAnimalsBacillus subtilisBacterial ProteinsCell MembraneDrug Delivery SystemsHumansMiceBacterial ProteinsBacillus subtilisCP: CancerDoxildrug deliverymicroparticlenanoparticleSpoIVAsporesporulationSpoVMsynthetic biology

Identifiers

PMID36640333
PMCPMC10009695
OpenAlexW4313491485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.